QPPV.COM KNOWLEDGE ASSESSMENT

Daclizumab Beta: Mechanism, EU Withdrawal and Pharmacovigilance

Test your understanding of the concepts covered by Daclizumab Beta: Mechanism, EU Withdrawal and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 A report describes encephalitis shortly after treatment cessation but provides no infectious work-up or assessment of multiple-sclerosis activity. Which conclusion is most appropriate?

The temporal association alone establishes a drug-induced immune reaction. The event must be attributed to multiple-sclerosis activity because the patient has that disease. Causality remains to be assessed; infection, multiple-sclerosis activity and other neurological causes should not be assumed away. The report cannot be considered because it occurred after treatment stopped.

Question 2 of 10 Which statement most accurately describes the EU regulatory history presented in the article?

The medicine was authorised in 2018 and withdrawn after an EU-wide efficacy failure. The medicine was authorised in July 2016 for adults with relapsing forms of multiple sclerosis; its authorisation was withdrawn on 27 March 2018 at the holder’s request after serious safety concerns. The medicine was authorised for all forms of multiple sclerosis and remains authorised with enhanced monitoring. The medicine was withdrawn in 2016 after reports limited to mild injection-site reactions.

Question 3 of 10 How should seriousness, expectedness and causality be handled in a case assessment?

Treat them as interchangeable conclusions and assign them together. Assess them separately because each addresses a different aspect of the safety report. Use seriousness alone to determine causality. Use the presence of a known safety concern to establish expectedness and causality automatically.

Question 4 of 10 Which statement is the most appropriate interpretation of the article’s clinical and regulatory status?

It is a historical safety account; daclizumab beta has no current EU marketing authorisation, and the article is not current treatment advice. It provides current prescribing instructions for an EU-authorised medicine. Withdrawal means historical adverse-event reports should no longer be assessed. The historical safety measures apply identically to every medicine targeting an immune pathway.

Question 5 of 10 Which combination of factors best supports a structured aggregate assessment of daclizumab beta safety reports?

Treatment period, restrictions, time since last dose, organ system, seriousness and diagnostic certainty. Report receipt date and reporter profession only. The total number of cases, with no assessment of timing or diagnosis. Only whether each patient received the final authorised dose.

Question 6 of 10 Which approach is most appropriate when interpreting an aggregate increase in reports of a particular event?

Treat the report count as the incidence rate if the reports are serious. Stratify reports by relevant exposure and clinical features, and do not infer incidence from report counts alone. Combine all treatment periods and event types to maximise the total count. Exclude reports arising after discontinuation before comparing cases.

Question 7 of 10 Which statement best describes the historical liver-monitoring period discussed in the article?

Monitoring was required only before the first dose. Historical safety measures required liver monitoring during treatment and for up to six months after stopping. Monitoring ended when the patient received the final dose. Monitoring was required for exactly six months after every dose, whether or not treatment stopped.

Question 8 of 10 A patient’s last dose was several months ago, and a serious suspected immune-mediated event is now reported. What is the most appropriate initial pharmacovigilance approach?

Exclude the event because the patient was no longer receiving treatment. Assess the event and preserve the chronology because serious events could present after discontinuation. Record the event only if treatment was restarted. Close the case at the last injection and omit subsequent clinical information.

Question 9 of 10 A case report includes a possible infection, but the assessment attributes the neurological event to daclizumab beta without discussing it. What is the most important improvement?

Evaluate the infection and other plausible explanations as competing diagnoses rather than attributing the event solely from timing. Delete the infection information because it is unrelated to pharmacovigilance. Assume that a suspected immune reaction cannot coexist with infection. Classify the case as unrelated solely because an alternative diagnosis was mentioned.

Question 10 of 10 Which set of product-specific exposure details is most appropriate to seek for a historical report?

Product, dose, route, batch or lot where available, administration dates, start and stop dates, duration, interruptions and last dose. Only the trade name and the date the report was received. Only the patient’s symptoms and outcome, because exposure history is not relevant after withdrawal. The patient’s current medicines, without information on daclizumab beta administration.

Daclizumab Beta: Mechanism, EU Withdrawal and Pharmacovigilance

Cookie Settings